Jefferies Starts Eli Lilly (LLY) at Hold, 'Priced to Perfection'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Jefferies Starts Eli Lilly (LLY) at Hold, 'Priced to Perfection'

Eli Lilly & Co. (LLY) Announces U.S. FDA Broadens Indication for Verzenio in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

March 3, 2023 3:00 PM EST

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following:... More